



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/789,403	02/27/2004	Andrea Crisanti	TROJAN1100-1	5324
28213	7590	07/23/2010	EXAMINER	
DLA PIPER LLP (US)			CARLSON, KAREN C	
4365 EXECUTIVE DRIVE				
SUITE 1100			ART UNIT	PAPER NUMBER
SAN DIEGO, CA 92121-2133			1656	
			MAIL DATE	DELIVERY MODE
			07/23/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/789,403	CRISANTI, ANDREA	
	Examiner	Art Unit	
	Karen Cochrane Carlson	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 02 July 2010.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-4 and 6-16 is/are pending in the application.

4a) Of the above claim(s) 2,3 and 7-12 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,4,6 and 13-16 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. 09/486,676.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>2/2004</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____ .

This Office Action is in response to the paper filed July 2, 2010.

Claim 5 has been cancelled. Claims 1-4, and 6-16 are currently pending. The Examiner has withdrawn Claims 2, 3, 7-12 from further consideration because these claims are drawn to non-elected inventions. Claims 1, 4, 6, and 13-16 are currently under examination.

Benefit of priority is to September 2, 1997.

Withdrawal of Objections and Rejections:

The objection to the disclosure because the priority information at page 1 needs to be updated is withdrawn.

The rejection of Claims 1, 4-6, and 13-16 under 35 U.S.C. 112, second paragraph, is withdrawn.

The rejection of Claims 1, 4, and 13-16 under 35 U.S.C. 102(b) as being anticipated by Schutze-Redelmeier et al. (IDS; July 15, 1996; Introduction of Exogenous antigens into the MHC Class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J. Immunol. 157: 650-655) is withdrawn due to the amendment of the Claim 1 to include the limitations of Claim 5.

Maintenance of Rejections:

Claims 1, 4, 6, 15 and 16 are again rejected under 35 U.S.C. 102(b) as being anticipated by Saffman et al. (1994; A differential response element for the homeotics at the antennapedia P1 promoter of Drosophila. Proc. Natl. Acad. Sci. 91: 7420-7424).

Saffman et al. teach fusion proteins comprising different regulatory elements of 3 different homeotic proteins, ultrabithorax (UBX), abdominal-A (ABD-A), and antennapedia (ANTP). Homeotic proteins are a family of related but distinct developmental regulators that specify the differences in the body segments of Drosophila (page 7420, left col., top). Saffman et al. teach fusion protein UAU in Fig. 3. The fusion protein UAU comprises the homeodomain of antennapedia and ultrabithorax homeoprotein N-terminal and C-tail. Fusion protein UAA comprises the homeodomain and C-tail of antennapedia and the N-terminal of ultraithorax. In both of these fusion proteins, the ultrabithorox N-terminal region is at least 225 amino acids because the deletional mutant of ultrabithorax (*UU) has amino acids 37-225 deleted (page 7421, right col., line above 1st full para.), and the depiction of this deletional mutant and the UAU and UAA fusion protein in Fig. 3 shows the N-terminal region of ultrabithorax as comprising these amino acids plus additional amino acids N- and C-terminal to this deleted region. The fusion proteins were recombinantly produced via transformation of S2 cells with expression vectors comprising nucleic acid encoding the fusion proteins. The fusion proteins were isolated via immunoblotting S2 extracts with UBX antibody (page 7421, right col., line 16-17). The "apparent molecular weight" was determined (page 7421, right col., line 17), indicating that the fusion proteins were not denatured.

Therefore, Saffman et al. teach a conjugate comprising a first region comprising the first homeodomain of antennapedia and a second ultrabithorax N-terminal region that is not naturally associated with the homeodomain of antennapedia and the fusion protein was not denatured, wherein the second ultrabithorax N-terminal region comprises at least 100 amino acids (**Claim 1**), wherein the conjugate is in the form of a fusion protein (**Claim 4**), and is a functional or regulatory protein (**Claim 6**). As noted above, the conjugates were produced recombinantly and isolated by UBX antibody affinity purification under non-denaturing conditions (**Claim 15**). Saffman et al. do not disclose where the UBX antibody binds within the isolated fusion. However, the UAU fusion protein comprises the UBX N- terminus and C-terminal tail, and the UAA comprises the N-terminus tail. Therefore, the fusion protein comprise an amino acid tail that binds to an immobilised substrate (**Claim 16**).

Applicants argue that the fusion proteins of Saffman et al. were constructed for the purpose of studying homeotic regulatory specificities for a particular promoter and that the fusion proteins comprising Antp were longer than the 180 bp sequences of Antp used in the instant invention. Applicants conclude that the protein fragments of Saffman et al. are all naturally associated. In response, the ultrabithorax (UBX), abdominal-A (ABD-A), and antennapedia (ANTP) proteins are homeotic proteins which are a family of related *but distinct developmental regulators* that specify the differences in the body segments of Drosophila. Therefore, these proteins are not naturally associated as a

Art Unit: 1656

fusion protein because they are distinct proteins. The reason for Saffman et al. to make the fusion proteins are not germane to the rejection.

Applicants then turn their arguments around and urge that because the fragments of the fusion proteins of Saffman et al. are not naturally associated with the antennapedia homeodomain, the second region has no functional regulatory effect on the first region and the antennapedia homeodomain is used to translocated a protein of at least 100 amino acids across the cell membrane. In response, Claim 1 only requires that the homeodomain of antennapedia be fused with a second region that is at least 100 amino acids in length and is not naturally associated with this homeodomain. Claim 6, for example, only requires that the second region be a functional or regulatory protein, which the N-terminal of ultrabithorax is, for example.

Art of Record:

Perez et al. (1994; Rab3A and Rab3B carboxy-terminal peptides are both potent and specific inhibitors of prolactin release by rat cultured anterior pituitary cells. Mol. Endocrin. 8: 1278-1287) teach a recombinantly produced fusion protein comprising the homeodomain of antennapedia and the entire Rab3A protein (page 1279, right col., para. 4; Fig 3; page 1284, right col., para. 4.). However, this fusion protein was purified via SDS-PAGE (page 1285, left col, line 4), which SDS is a reducing/denaturing agent. Using this same purification method for fusion proteins comprising the homeodomain of antennapedia and smaller fragments of Rab3A, Perez et al. demonstrate that these

fusion proteins could translocated across cell membranes while the fusion proteins with the full-length Rab3A could not.

New Rejection:

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 6 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 6 continues to depend from cancelled Claim 5. For examination purposes, Claim 6 was taken to depend from Claim 1.

No claims are allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Art Unit: 1656

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson whose telephone number is 571-272-0946. The examiner can normally be reached on 6:00 AM - 4:00 PM, Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen Cochrane Carlson/
Primary Examiner, Art Unit 1656